Oncolytics Biotech (TSE:ONC) Upgraded to Strong-Buy at Lake Street Capital

Oncolytics Biotech (TSE:ONC) was upgraded by analysts at Lake Street Capital to a “strong-buy” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Separately, Jones Trading cut shares of Oncolytics Biotech from a “strong-buy” rating to a “hold” rating in a report on Friday, May 16th.

Oncolytics Biotech Price Performance

Oncolytics Biotech stock opened at C$1.34 on Wednesday. The company has a quick ratio of 8.86, a current ratio of 2.99 and a debt-to-equity ratio of 11.75. Oncolytics Biotech has a 52-week low of C$0.44 and a 52-week high of C$2.08. The company has a market cap of C$103.28 million, a price-to-earnings ratio of -3.73 and a beta of 1.35. The firm’s fifty day moving average is C$1.23 and its 200 day moving average is C$0.97.

Insiders Place Their Bets

In other news, Senior Officer Andrew P. Aromando acquired 25,500 shares of the firm’s stock in a transaction on Tuesday, July 15th. The shares were bought at an average price of C$1.62 per share, for a total transaction of C$41,425.92. Also, Senior Officer Jared Ryan Kelly acquired 50,400 shares of the firm’s stock in a transaction on Wednesday, July 16th. The stock was purchased at an average price of C$1.63 per share, for a total transaction of C$82,284.50. Insiders have acquired a total of 108,300 shares of company stock worth $178,192 in the last three months. Corporate insiders own 3.82% of the company’s stock.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.